Cardiovascular Diabetology

Table 2 Physical and 2DE structural and functional parameters at baseline

From: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

	Level	Parameter	Group
	Level	Parameter	Control	Empagliflozin
		Body weight [gr]	413 ± 35	395 ± 37
Apical level	Systolic	LVESA [mm²]	16.4 ± 5.9	15.8 ± 5.3
	Systolic	LVIDs [mm]	4.2 ± 0.7	4.6 ± 0.7
	Diastolic	LVEDA [mm²]	43.3 ± 4.9	39.2 ± 5.4
	Diastolic	LVIDd [mm]	7.6 ± 0.6	7.0 ± 0.6
	Function	FS [%]	39.7 ± 3.9	35.6 ± 3.8
		FAC [%]	63.1 ± 3.7	59.0 ± 3.7
		EF [%]	74.5 ± 6.4	70.4 ± 6.2
Papillary muscles level	Systolic	LVESA [mm²]	20.5 ± 4.3	26.2 ± 4.3
	Systolic	LVIDs [mm]	4.3 ± 0.6	4.9 ± 0.7
	Diastolic	LVEDA [mm²]	51.2 ± 4.7	47.1 ± 4.6
	Diastolic	LVIDd [mm]	7.5 ± 0.6	7.3 ± 0.5
	Function	FS [%]	36.2 ± 3.1	39.7 ± 3.2
		FAC [%]	52.3 ± 3.6	56.2 ± 4.0
		EF [%]	69.9 ± 5.3	76.4 ± 5.4

LVESA, LVEDA—LV end systolic and end diastolic area, respectively. LVIDs, LVIDd—LV end systolic and end diastolic internal diameter, respectively. FS fractional shortening, FAC fractional area change, EF ejection fraction

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com